skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 10,000  for All Library Resources

Results 1 2 3 4 5 next page
Refined by: resource type: Newsletter Articles remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
European Journal of Pediatrics Issues Research Articles in May 2024 Edition
Material Type:
Newsletter Article
Add to My Research

European Journal of Pediatrics Issues Research Articles in May 2024 Edition

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

2
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
Material Type:
Newsletter Article
Add to My Research

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

PR Newswire, 2024

Copyright PR Newswire Association LLC May 7, 2024

Digital Resources/Online E-Resources

3
Congenital Adrenal Hyperplasia Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma
Material Type:
Newsletter Article
Add to My Research

Congenital Adrenal Hyperplasia Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma

M2 Presswire, 2024

Copyright © M2 Communications, 2024

Digital Resources/Online E-Resources

4
Rezolute (NV) (RZLT: $3.27) drops 1.2%, 3 days' volume in a day; -4c [1.2%] Vol Index 3.0 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Rezolute (NV) (RZLT: $3.27) drops 1.2%, 3 days' volume in a day; -4c [1.2%] Vol Index 3.0 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 7, 2024

Digital Resources/Online E-Resources

5
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
Material Type:
Newsletter Article
Add to My Research

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)

Business Wire, 2024

Copyright Business Wire 2024

Digital Resources/Online E-Resources

6
Human Molecular Genetics Issues Research Articles in May 15, 2024 Edition
Material Type:
Newsletter Article
Add to My Research

Human Molecular Genetics Issues Research Articles in May 15, 2024 Edition

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

7
Weekly: Rezolute (NV) (RZLT: $3.31) soars 24% on robust volume; +65c [24.4%] Vol Index 1.4 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Weekly: Rezolute (NV) (RZLT: $3.31) soars 24% on robust volume; +65c [24.4%] Vol Index 1.4 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 6, 2024

Digital Resources/Online E-Resources

8
Masimo Receives FDA Clearance for Stork™ Over-the-Counter (OTC) Baby Monitoring System
Material Type:
Newsletter Article
Add to My Research

Masimo Receives FDA Clearance for Stork™ Over-the-Counter (OTC) Baby Monitoring System

Business Wire, 2024

Copyright Business Wire 2024

Digital Resources/Online E-Resources

9
An alternative for cardiac patients
Material Type:
Newsletter Article
Add to My Research

An alternative for cardiac patients

CE Noticias Financieras, 2024

CE Noticias Financieras English, Latin America - Distributed by ContentEngine LLC

Digital Resources/Online E-Resources

10
Rezolute (NV) (RZLT: $3.31) accelerates rise, up 24% in 3 days; +63c [23.5%] Vol Index 1.4 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Rezolute (NV) (RZLT: $3.31) accelerates rise, up 24% in 3 days; +63c [23.5%] Vol Index 1.4 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 4, 2024

Digital Resources/Online E-Resources

11
UPDATE: Lantheus Holdings (LNTH: $75.53) down 3.4% on analyst downgrade; -$2.65 [3.4%] Vol Index 1.6 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

UPDATE: Lantheus Holdings (LNTH: $75.53) down 3.4% on analyst downgrade; -$2.65 [3.4%] Vol Index 1.6 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 4, 2024

Digital Resources/Online E-Resources

12
UCL Professors Makes First TIME100 Health List
Material Type:
Newsletter Article
Add to My Research

UCL Professors Makes First TIME100 Health List

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

13
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
Material Type:
Newsletter Article
Add to My Research

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024

PR Newswire, 2024

Copyright PR Newswire Association LLC May 3, 2024

Digital Resources/Online E-Resources

14
Hong Kong: CHP investigates one imported infection case of Zika virus
Material Type:
Newsletter Article
Add to My Research

Hong Kong: CHP investigates one imported infection case of Zika virus

Hong Kong Government News, 2024

Copyright 2017 Contify.com

Digital Resources/Online E-Resources

15
New Transformative Leadership Team Announced for Texas Children's World-Renowned Heart Center
Material Type:
Newsletter Article
Add to My Research

New Transformative Leadership Team Announced for Texas Children's World-Renowned Heart Center

PR Newswire, 2024

Copyright PR Newswire Association LLC May 3, 2024

Digital Resources/Online E-Resources

16
UPDATE: Lantheus Holdings top gainer in Clearview Wealth Advisors climbs 8.3% in 34 days, hits 274-day high; +$10.79 [16.0%] Vol Index 3.2 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

UPDATE: Lantheus Holdings top gainer in Clearview Wealth Advisors climbs 8.3% in 34 days, hits 274-day high; +$10.79 [16.0%] Vol Index 3.2 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 3, 2024

Digital Resources/Online E-Resources

17
Rezolute (NV) (RZLT: $2.97) accelerates rise, up 11% in 2 days; +29c [10.8%]
Material Type:
Newsletter Article
Add to My Research

Rezolute (NV) (RZLT: $2.97) accelerates rise, up 11% in 2 days; +29c [10.8%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 3, 2024

Digital Resources/Online E-Resources

18
Sexually transmitted diseases on the rise
Material Type:
Newsletter Article
Add to My Research

Sexually transmitted diseases on the rise

CE Noticias Financieras, 2024

CE Noticias Financieras English, Latin America - Distributed by ContentEngine LLC

Digital Resources/Online E-Resources

19
Case Reports Issues Research Articles in May 1, 2024 Edition
Material Type:
Newsletter Article
Add to My Research

Case Reports Issues Research Articles in May 1, 2024 Edition

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

20
Rezolute (NV) (RZLT: $2.76) climbs 3.0% against the trend; +8c [3.0%]
Material Type:
Newsletter Article
Add to My Research

Rezolute (NV) (RZLT: $2.76) climbs 3.0% against the trend; +8c [3.0%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 2, 2024

Digital Resources/Online E-Resources

Results 1 - 20 of 10,000  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 2001  (14)
  2. 2001 To 2006  (59)
  3. 2007 To 2012  (524)
  4. 2013 To 2019  (2,621)
  5. After 2019  (6,783)
  6. More options open sub menu

Subject 

  1. Pediatrics  (2,286)
  2. Cardiovascular Disease  (2,279)
  3. Clinical Trials  (2,055)
  4. Pharmaceutical Industry  (1,681)
  5. Heart  (1,668)
  6. Patients  (1,531)
  7. Disease  (1,367)
  8. Fda Approval  (1,345)
  9. Biotechnology Industry  (1,318)
  10. R&d  (1,297)
  11. Research & Development  (1,297)
  12. Covid-19  (1,215)
  13. Stockholders  (1,152)
  14. Earnings Per Share  (1,067)
  15. Net Losses  (1,038)
  16. Hospitals  (886)
  17. Coronaviruses  (880)
  18. Webcasting  (873)
  19. Drug Dosages  (871)
  20. More options open sub menu

Language 

  1. English  (9,989)
  2. Urdu  (11)
  3. Spanish  (5)
  4. German  (4)
  5. Portuguese  (2)
  6. More options open sub menu

Searching Remote Databases, Please Wait